Aspen Aerogels (NYSE:ASPN) Updates FY 2025 Earnings Guidance

Aspen Aerogels (NYSE:ASPN) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -4.150–4.050 for the period, compared to the consensus estimate of -0.140. The company issued revenue guidance of $270.0 million-$280.0 million, compared to the consensus revenue estimate of $303.3 million.

Aspen Aerogels Trading Down 6.7%

ASPN stock traded down $0.28 during mid-day trading on Friday, reaching $3.84. 7,417,826 shares of the stock traded hands, compared to its average volume of 2,045,192. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.31 and a current ratio of 3.98. Aspen Aerogels has a one year low of $3.70 and a one year high of $17.56. The stock has a market capitalization of $315.85 million, a PE ratio of -1.00 and a beta of 2.85. The business has a 50-day moving average price of $7.35 and a two-hundred day moving average price of $6.77.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings data on Thursday, November 6th. The construction company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.05). The firm had revenue of $73.02 million during the quarter, compared to the consensus estimate of $73.42 million. Aspen Aerogels had a positive return on equity of 2.92% and a negative net margin of 78.53%.The firm’s revenue for the quarter was down 37.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) EPS. Aspen Aerogels has set its FY 2025 guidance at -4.150–4.050 EPS. Equities research analysts expect that Aspen Aerogels will post 0.17 EPS for the current year.

Analysts Set New Price Targets

ASPN has been the topic of a number of recent analyst reports. Canaccord Genuity Group reduced their target price on Aspen Aerogels from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Aspen Aerogels in a report on Wednesday, October 8th. Finally, Barclays dropped their price objective on Aspen Aerogels from $6.00 to $4.00 and set an “underweight” rating on the stock in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.50.

Insider Activity

In related news, CAO Santhosh P. Daniel sold 4,410 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.31, for a total transaction of $32,237.10. Following the sale, the chief accounting officer owned 19,879 shares of the company’s stock, valued at $145,315.49. This trade represents a 18.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Aspen Aerogels

A number of institutional investors have recently modified their holdings of ASPN. Vanguard Group Inc. lifted its position in Aspen Aerogels by 0.5% during the third quarter. Vanguard Group Inc. now owns 4,510,370 shares of the construction company’s stock valued at $31,392,000 after acquiring an additional 22,686 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Aspen Aerogels by 29.1% during the second quarter. Osaic Holdings Inc. now owns 10,615 shares of the construction company’s stock worth $63,000 after purchasing an additional 2,390 shares in the last quarter. Caxton Associates LLP lifted its holdings in shares of Aspen Aerogels by 114.9% during the 2nd quarter. Caxton Associates LLP now owns 103,172 shares of the construction company’s stock valued at $611,000 after purchasing an additional 55,167 shares during the last quarter. FORA Capital LLC boosted its position in shares of Aspen Aerogels by 138.2% in the 2nd quarter. FORA Capital LLC now owns 29,452 shares of the construction company’s stock worth $174,000 after purchasing an additional 17,090 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Aspen Aerogels by 184.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,235 shares of the construction company’s stock worth $43,000 after buying an additional 4,693 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.